SCHEMBL864407

SCHEMBL864407

CCCC(=O)c1ccc(OCCN(C)C)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 5/20 0.72
THRB P10828 3/20 0.72
L3MBTL1 Q9Y468 1/20 0.62
ESR1 P03372 2/20 0.57
EGFR P00533 3/20 0.56
MAPT P10636 4/20 0.55
STS P08842 1/20 0.55
MMP1 P03956 1/20 0.55
ALDH1A1 P00352 1/20 0.55
NPC1 O15118 2/20 0.53
MEN1 O00255 1/20 0.52
NR1I2 O75469 1/20 0.52
PRKD3 O94806 1/20 0.52
ABCB11 O95342 1/20 0.52
GBA1 P04062 1/20 0.52
NR3C1 P04150 1/20 0.52
ERBB2 P04626 1/20 0.52
TP53 P04637 1/20 0.52
PRKCG P05129 1/20 0.52
CYP1A2 P05177 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14287619 0.92 THRA (0.74) THRATHRBL3MBTL1EGFRMAPT
SCHEMBL19659861 0.90 THRA (0.80) THRATHRBL3MBTL1ESR1STS
SCHEMBL7598204 0.87 THRA (0.62) THRATHRBL3MBTL1ESR1EGFR
SCHEMBL17871437 0.86 THRA (0.62) THRATHRBL3MBTL1ESR1EGFR
SCHEMBL864569 0.86 EBP (0.63) THRATHRBL3MBTL1ESR1EGFR
SCHEMBL13753195 0.85 L3MBTL1 (0.77) THRATHRBL3MBTL1MAPTMMP1
SCHEMBL21002194 0.84 THRA (0.59) THRATHRBL3MBTL1ESR1EGFR
SCHEMBL17884768 0.84 ESRRB (0.62) THRATHRBL3MBTL1ESR1EGFR
SCHEMBL631740 0.83 THRA (0.57) THRATHRBESR1EGFRMAPT
SCHEMBL27395037 0.83 THRA (0.57) THRATHRBESR1EGFRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619184-B1 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2018-05-23 EP disclosed
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UNIV MICHIGAN (US) 2014-12-04 US disclosed
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UNIV MICHIGAN (US) 2014-12-04 US disclosed
US-8809377-B2 Deubiquitinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-08-19 US disclosed
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 US disclosed
WO-2012040527-A2 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UCHL1, USP2, USP1 THRA 4740/4885THRB 4510/4885L3MBTL1 369/4885
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UCHL1, USP2, USP1 THRA 4740/4885THRB 4510/4885L3MBTL1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.